The minimally invasive procedure was performed as part of a clinical trial, according to a March 7 news release from the hospital. The procedure is used to treat tricuspid regurgitation, which affects an estimated 1.6 million Americans.
The valve is replaced by inserting a catheter through the major vein of the leg. The procedure was performed by Gagan Singh, MD, who will monitor patients participating in the TTVR clinical trial for five years.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
